400 Technology Square
4 articles with Akero Therapeutics
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
Akero Therapeutics, Inc. announced the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA next week.
Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases
The financing will support the advancement of Akero's lead clinical candidate AKR-001
Akero Therapeutics Inc., a biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced the appointment of Mark Iwicki, chairman and CEO of Kala Pharmaceuticals, to Akero's Board of Directors.